article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

These molecules synthesised newly are packaged densely into custom lipid nanoparticles (LNPs), which Orna has made to act on the body’s crucial tissues. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

article thumbnail

Biggest ever analytica Anacon India, India Lab Expo, Pharma Pro&Pack Expo in Hyderabad”

Express Pharma

This is the largest-ever edition of the event in Hyderabad and with this year’s theme, ‘Epicentre of Progress’, the event showcases solutions for the entire value chain, from research to end-of-line packaging.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

At Agilent, we believe that sustainability, productivity and efficiency can co-exist in a lab without compromising on ROI

Express Pharma

Whereas proper disposal of unused medications, as well as initiatives to reduce packaging waste, chemical waste, and improve recycling programmes, will aid in pro-actively addressing this challenge. This may involve the use of eco-friendly raw materials, green manufacturing processes, and eco-friendly packaging.

article thumbnail

Merck to support development of Orna’s circular RNA (oRNA) therapies

European Pharmaceutical Review

Newly synthesised oRNA molecules are more compactly packaged into custom LNPs, which Orna has engineered to target key tissues in the body. Orna’s proprietary oRNA technology creates circular RNAs from linear RNAs by self-circularisation. We look forward to working with the talented scientific and technical teams at Orna.”